Aspartyl proteinase, phospholipase, hemolytic activities and biofilm production of Candida albicans isolated from bronchial aspirates of ICU patients

Medical Mycology

Volumn 49, Issue 1, 2010, Pages 94-97

  Sacristan B ^a   Blanco, M T ^a   Galan Ladero M A ^a   Blanco, J ^a   Perez Giraldo C ^a   Gomez Garca A C ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Aspartyl proteinases; Biofilm; Candida albicans; Hemolysins; Phospholipases

Indexed keywords

ASPARTIC PROTEINASE; PHOSPHOLIPASE; VIRULENCE FACTOR;

ARTICLE; ARTIFICIAL VENTILATION; BIOFILM; CANDIDA ALBICANS; ENZYME ACTIVITY; FUNGAL STRAIN; FUNGUS ISOLATION; HEMOLYSIS; HOSPITAL PATIENT; IN VITRO STUDY; INTENSIVE CARE UNIT; LUNG ASPIRATION; NONHUMAN;

ASPARTIC ACID PROTEASES; BIOFILMS; BRONCHI; CANDIDA ALBICANS; HEMOLYSIS; HUMANS; INTENSIVE CARE UNITS; PHOSPHOLIPASES; RESPIRATION, ARTIFICIAL; VIRULENCE FACTORS;

CANDIDA ALBICANS;

EID: 78650393401     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.482947     Document Type: Article

References (29)

1. Dongari-Bagtzoglou A, Dwivedi P, Ioannidou E, et al. Oral Candida infection and colonization in solid organ transplant recipients. Oral Microbiol Immunol 2009; 24: 249-254.
2. Leone M, Delliaux S, Bourgoin A, et al. Risk factors for late-onset ventilator-associated pneumonia in trauma patients receiving selective digestive decontamination. Intensive Care Med 2005; 31: 64-70.
3. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 2000; 13: 122-143.
4. Naglik JR, Challacombe J, Hube B. C andida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Review 2003; 67: 400-428.
5. Schaller M, Borelli C, Korting HC, Hube B . Hydrolytic enzymes as virulence factors of Candida albicans . Mycoses 2005; 48: 365-377.
6. Douglas, LJ. Medical importance of biofi lms in Candida infections. Rev Iberoam Micol 2002; 19: 139-143.
7. Ramage G, VandeWalle K, Wickes BL, López-Ribot JL. Characteristics of biofi lms formation by Candida albicans . Rev Iberoam Micol 2001; 18: 163-170
8. Hazen KC, Howell SA. Candida , Cryptococcus and other yeasts of medical importance. In: Murray PR, Baron E, Pfaller MA, Yolken RH (eds.). Manual of Clinical Microbiology, 8th edn. Washington, DC: ASM Press, 2003: 1693-1711.
9. Galán-Ladero M, Blanco MT, Sacrist á n B, et al. Enzymatic activities od Candida tropicalis isolated from hospitalized patients. Med Mycol 2009; 9: 1-4.
10. Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipases activity in Candida albicans . Sabouradia 1982; 20: 7-14.
11. Willianson MI, Samaranayake LP, MacFarlane TW. Phospholipase activity as a criterion for byotiping Candida albicans . J Med Vet Mycol 1986; 24: 415-417.
12. De Bernardis F, Sullivan PA, Cassone A. Aspartil proteinases of Candida albicans and their role in pathogenicity. Med Mycol 2001; 39: 303-313.
13. Manns JM, Mosser DM, Buckley HR. Production of a haemolytic factor by Candida albicans . Infect Immun 1994: 62: 5154-5156
14. Luo G, Samaranayake LP, Yau, JY. C andida species exhibit differential in vitro haemolytic activities. J Clin Microbiol 2001; 39: 2971-2974.
15. Meersseman W, Lagrou K, Spriet I, et al. Signifi cance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Int Care Med 2009; 35: 1526-1531.
16. Borst A, Fluit AC. High levels of hydrolytic enzymes secreted by Candida albicans isolates involved in respiratory infections. J Med Microbiol 2003; 52: 971-974
17. Kantarcioglu AS, Yucel A. Phospholipase and protease activities in clinical Candida isolates with reference to the sources of strains. Mycoses 2002; 45: 160-165.
18. Kumar CP, Suresh J, Kumar S, Menon T. Phospholipase and proteinases activities of clinical isolates of Candida from immunocompromised patients. Mycopathologia 2006; 161: 213-218.
19. Tsang CS, Chu FC, Leung WK, et al. Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus. J Med Microb 2007; 56: 1393-1398.
20. Odds FC. Secreted proteinases and C andida albicans virulence. Microbiology 2008; 154: 3245-3246.
21. Lermann U, Morschhä user J. Secreted aspartic proteases are not required for invasion of reconstituted human epithelium by Candida albicans . Microbiology 2008; 154: 3281-3295.
22. Naglik JR, Moyes D, Makwana J, et al. Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology 2008; 154: 3266-3280.
23. Consolaro ME, Gasparetto A, Svidzinski TI, Peralta RM. Effect of pepstatin A on the virulence factors of Candida albicans strains isolated from vaginal environment of patients in three different clinical conditions. Mycopathologia 2006; 162: 75-82.
24. Blanco MT, Hurtado C, P é rez-Giraldo C, et al. Effects of ritonavir and saquinavir on Candida albicans . Med Mycol 2003; 41: 167-170.
25. Li X, Yan Z, Xu J. Quantitative variation of biofi lms among strains in natural populations of Candida albicans . Microbiology 2003; 149: 353-362.
26. Ramage G, Saville SP, Wickes BL, López-Ribot JL. Inhibition of Candida albicans biofi lm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002; 68: 5459-5463.
27. Mendes A, Mores AU, Carvalho AP, et al. Candida albicans biofi lms produce more secreted aspartyl protease than the planktonic cells. Biol Pharm Bull 2007; 30: 1813-1815.
28. Gokce G, Cerikcioglu N, Yagci A. Acid proteinases, phospholipases, and biofi lm production of Candida species isolated from blood cultures. Mycopathologia 2007; 164: 265-269.
29. Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. Int J Microbiol 2008; 32: S87-S91.